ModerateVitamin K antagonist anticoagulants×Antiepileptics. Carboxamide derivatives
Updated · Methodology
Mechanism
Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Carbamazepine is a potent inducer of CYP3A4 and other liver enzyme systems (carbamazepine SmPC, AEMPS). According to the US label, it also induces CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 and may lower the levels of drugs mainly metabolised by these enzymes (carbamazepine prescribing information, US Food and Drug Administration, FDA). The Spanish carbamazepine SmPC names acenocoumarol explicitly among the oral anticoagulants whose plasma levels and effect carbamazepine can reduce or even abolish (carbamazepine SmPC, AEMPS). The acenocoumarol SmPC lists carbamazepine among drugs that can reduce its anticoagulant effect (acenocoumarol SmPC, AEMPS). Of the coumarins, the US carbamazepine label names only warfarin and dicoumarol (carbamazepine prescribing information, FDA).
Symptoms
The effect of acenocoumarol can weaken or even disappear (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens. After carbamazepine is stopped, the effect of acenocoumarol can increase again, especially if its dose was raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).
Management
The combination is not contraindicated but needs close coagulation monitoring. The acenocoumarol summary of product characteristics (SmPC) lists carbamazepine among drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, both when such a drug is added and when it is stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the Spanish carbamazepine SmPC, the dose of oral anticoagulants, including acenocoumarol, is adjusted to clinical requirements (carbamazepine SmPC, AEMPS). According to the US carbamazepine label, concentration monitoring or dose adjustment may be needed with warfarin (carbamazepine prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Carbamazepina (nº registro 62621), sección 4.5 (2025)– AEMPS, CIMA, nº registro 62621, sección 4.5
- AEMPS: Ficha técnica: Carbamazepina, Tegretol 200 mg (nº registro 39955), sección 4.5 (2026)– AEMPS, CIMA, nº registro 39955, revisión 09/2026, secciones 4.3 y 4.5
- FDA: Tegretol (carbamazepine) prescribing information (2026)– FDA label, DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053, version 39, revised 08/2026, Contraindications and PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2